Pfizer (PFE) PT Set at $53.00 by Cantor Fitzgerald

Pfizer (NYSE:PFE) has been assigned a $53.00 target price by research analysts at Cantor Fitzgerald in a report issued on Thursday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 19.69% from the stock’s previous close.

A number of other analysts also recently weighed in on the company. Citigroup boosted their target price on Pfizer from $34.00 to $37.00 and gave the stock a “sell” rating in a research report on Tuesday. BMO Capital Markets downgraded Pfizer from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $47.00 to $46.00 in a research report on Thursday, November 1st. They noted that the move was a valuation call. Societe Generale set a $43.00 target price on Pfizer and gave the stock a “hold” rating in a research report on Thursday, November 1st. Credit Suisse Group restated a “neutral” rating and issued a $40.00 target price on shares of Pfizer in a research report on Tuesday, October 30th. Finally, Goldman Sachs Group restated a “neutral” rating and issued a $45.00 target price on shares of Pfizer in a research report on Tuesday, October 30th. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $42.67.

Shares of PFE opened at $44.28 on Thursday. The stock has a market cap of $256.03 billion, a PE ratio of 16.71, a price-to-earnings-growth ratio of 2.17 and a beta of 0.88. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.41. Pfizer has a 12-month low of $33.20 and a 12-month high of $45.81.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.03. The firm had revenue of $13.30 billion during the quarter, compared to the consensus estimate of $13.53 billion. Pfizer had a return on equity of 25.34% and a net margin of 44.63%. The company’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter last year, the company posted $0.67 EPS. On average, equities analysts forecast that Pfizer will post 3 earnings per share for the current year.

In other Pfizer news, insider Laurie J. Olson sold 10,214 shares of Pfizer stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $41.00, for a total value of $418,774.00. Following the transaction, the insider now directly owns 72,672 shares of the company’s stock, valued at approximately $2,979,552. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Pfizer Inc purchased 55,556 shares of the firm’s stock in a transaction on Monday, October 15th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $1,000,008.00. Following the completion of the purchase, the insider now directly owns 21,976,484 shares in the company, valued at $395,576,712. The disclosure for this purchase can be found here. 0.06% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in PFE. Fort L.P. purchased a new position in shares of Pfizer during the second quarter valued at approximately $121,000. W.G. Shaheen & Associates DBA Whitney & Co purchased a new position in shares of Pfizer during the first quarter valued at approximately $132,000. Braun Bostich & Associates Inc. purchased a new position in shares of Pfizer during the first quarter valued at approximately $139,000. Smart Portfolios LLC increased its stake in shares of Pfizer by 43.9% during the second quarter. Smart Portfolios LLC now owns 3,935 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 1,200 shares during the period. Finally, Selective Wealth Management purchased a new position in shares of Pfizer during the third quarter valued at approximately $155,000. 68.96% of the stock is currently owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Further Reading: What is the float in trading stocks?

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply